- Home
- BDJ vs TVTX Comparison
BDJ vs TVTX Comparison
Compare BDJ & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDJ | TVTX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.8B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BDJ | TVTX |
|---|---|---|
| Price | $9.00 | $31.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $37.08 |
| AVG Volume (30 Days) | 459.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $43.88 |
| Revenue Next Year | N/A | $33.16 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $13.14 |
| 52 Week High | $9.76 | $42.13 |
Technical Indicators
Market Signals| Indicator | BDJ | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 61.38 |
| Support Level | $8.92 | $30.92 |
| Resistance Level | $9.20 | $33.14 |
| Average True Range (ATR) | 0.13 | 1.48 |
| MACD | 0.06 | 0.58 |
| Stochastic Oscillator | 94.26 | 72.22 |
Price Performance
Historical ComparisonAbout BDJ Blackrock Enhanced Equity Dividend Trust
BlackRock Enhanced Equity Dividend Trust is a United States closed-end management investment company. Its investment objective is to seek current income and current gains, with a secondary objective of long-term capital appreciation.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.